Project Grant HT94252310197

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $427,625.00 to The Washington University in St. Louis to develop a novel in vitro model for studying amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The research project will employ direct neuronal conversion to generate induced motor neurons and cortical...

This $645,391 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, will fund research to investigate the effects of re-expressing embryonic motor neuron selector transcription factors ISL1 and LHX3 in mouse models of amyotrophic lateral sclerosis (ALS) and in induced pluripotent stem cell-derived ALS motor neurons. The goal is to examine whether restoring the expression of these factors in mature motor...

This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $107,948 to New York University School of Medicine to conduct research on the transcription factors that control human motor neuron cell fate. The award aims to further characterize the roles of two sets of transcription factors identified through prior CRISPR screening approaches - the...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $532,381 to Emory University to comprehensively investigate the molecular mechanisms underlying the role of the KIF5A gene variant KIF5ADE27 in the pathogenesis of amyotrophic lateral sclerosis (ALS). The research aims to determine the gain-of-function effects of KIF5ADE27 in...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, aims to develop advanced base and prime editing strategies to correct common ALS-causing SOD1 mutations. The $124,246 award, with a performance period from December 1, 2024 to November 30, 2026, will support the University of Massachusetts Medical School in the following key...

This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program provides $120,504 to Carnegie Mellon University to develop peptide nucleic acid (PNA) oligomers for targeted disruption of biomolecular condensates in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The key objectives are to: (a) fluorescently label RNAs suspected of participating in biomolecular condensates, and (b) disrupt...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is supporting the development and optimization of a new animal model for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The $374,349 award to the University of North Carolina at Chapel Hill aims to demonstrate the progressive ALS/FTD-like phenotype in aged cohorts of...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $2,307,075 to The Leland Stanford Junior University to support an ambitious research program aimed at defining novel mechanisms of human neurodegenerative diseases and translating those findings into potential new therapies. The key products and services to be delivered...

This Project Grant award, with ID K99NS140635, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The $121,554 award supports research to investigate the impact of KIF5A gene mutations on RNA processing and their role in the development of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. The research objectives include...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...